CGTLive®’s Weekly Rewind – November 21, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Bladder Cancer Gene Therapy Detalimogene Effects 62% CRR at 6 Months Posttreatment

This finding came from an analysis of 37 patients treated in the phase 1/2 LEGEND trial.

2. Derek Ansel, MS, CGC, on the Growing Role of Genetic Counselors in Clinical Trials

The vice president of Rare Disease Strategy at Worldwide Clinical Trials discussed the increasing importance of genetic counselors in clinical trials with regard to design, execution, and interpretation.

3. Stephen M. Ansell, MD, PhD, on Integrating Cell Therapy into Clinical Practice in Oncology

The chair of the Division of Hematology at Mayo Clinic discussed practical considerations for the introduction of cell therapies for the treatment of hematologic malignancies.

4. Platform Approaches and Industry Investment in Cell and Gene Therapy

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, spoke about strategies for streamlining development of novel therapies.

5. Sara Pirzadeh-Miller, MS, CGC, on AI and Gene Therapy Working in Tandem

The president of the National Society of Genetic Counselors discussed AI and gene therapy, which constituted key topics at NSGC's annual conference this year.